Variations in herpes zoster manifestation

Uwe Wollina

Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany

Received October 3, 2017

Herpes zoster (HZ) is a neurocutaneous disorder due to endogenous reactivation of the varicella-zoster virus (VZV). The typical clinical manifestation is an acute segmental eruption of herpetiform umbilicated vesicles associated with malaise, pain, dysaesthesia, allodynia and probably fever. This review focuses on other possible clinical manifestations of the disease to sensitize physicians not to overlook HZ since only an early antiviral treatment can reduce the risk of post-zosteric neuralgia.

Key words Clinical findings - herpes zoster - varicella-zoster virus

Introduction

Herpes zoster (HZ) is a viral disease caused by endogenous reactivation of an infection by the varicella-zoster virus (VZV). Clinically, the disease is characterized by an acute segmental (dermatomal) eruption of herpetiform vesicles on the skin and/or mucosa. Epidemiologic data from Europe and the US suggest a yearly incidence rate of 4 to 5 per 1000 person-years. Incidence increases with age. HZ is more common among females in all age groups. In Germany, HZ morbidity has been reported to be 0.29 for females and 0.10 for males per 100,000 patient-years. Patients at risk for HZ are those with one of the following underlying disorders and treatments: autoimmune diseases, asthma, diabetes, treatment with biologics or immunosuppressants, cancer or HIV/AIDS.

Clinical presentation

The prodromal phase of about one to five days is characterized by malaise, fever and pain. The classical clinical presentation of herpetiform umbilication within a dermatoma allows a visual diagnosis without the need for extensive diagnostic procedures. Later on, crusts develop that disappear within one or two weeks without leaving scars (Fig. 1).

The classical feature, however, may not always be present making diagnosis more challenging. A typical prodromal stage of HZ ophthalmicus is Hutchinson’s sign: vesicles develop on the tip of the nose or on the side of the nose due to the involvement of the nasociliary branch of the trigeminal nerve, which innervates both the cornea and the nose. Hutchinson’s sign is more common among patients with immunosuppression or immunodeficiency.

Herpes zoster with extended prodrome

HZ prodrome extending five days and up to 18 days have been reported. Extended prodrome is not necessarily associated with immunosuppression or immunodeficiencies.
Herpes zoster not respecting dermatoma borders

Some aberrant vesicles are not uncommon. However, HZ not respecting the borders of a dermatoma may be due to viraemic spread indicating a more severe subtype. HZ duplex is crossing the midline of the body. This subtype is seen more often in Asia than in Europe. An association to immunologic aberrations is present in <50 per cent of patients. Multi-segmental HZ and generalized HZ represent a continuum of more severe manifestations (Fig. 2A, B).

Herpes zoster leaving scars

If the inflammation is very strong, protracted scars may develop. This can be seen in haemorrhagic and necrotic HZ (Figs 3 & 4). Healing is delayed and bacterial superimposed infection is an additional risk (Fig. 5). Necrosis can also develop after unremarkable HZ due to delayed nervous and vascular compromise. This subtype is most commonly seen in the head-and-neck region. The development of keloids after HZ has been reported in a pregnant woman.

Herpes zoster with vascular manifestations

VZV vasculopathy covers a broad range of vascular manifestations in both immunocompetent and immunocompromised patients. Ischaemic stroke and intracerebral aneurysms may develop after VZV infection of cerebral arteries. In patients ≥65 yr of age, HZ increases the risk of myocardial infarction 1.7-fold and of ischaemic stroke 2.4-fold during the first week of disease.

Leucocytoclastic VZV vasculitis can be a consequence of HZ. VZV can even trigger the onset of temporal arteritis. Erythema multiforme (EM)-linked lesions have been observed in HZ patients. HZ has been reported to increase the risk of peripheral arterial disease by 13 per cent.

Herpes zoster associated with neurologic impairment

An overview of specific neurological consequences of HZ is summarized in the Table. The central nervous system...
system can be affected by HZV. Such patients suffer from headache, neck stiffness, behavioural abnormalities and somnolence. Typical manifestations are encephalitis and meningitis in addition to VZV vasculopathy. The diagnosis is hampered in particular in elderly patients with multiple comorbidities. Cerebrospinal fluid analysis is not always helpful since pleocytosis can be found even in uncomplicated HZ, but increased virus load is characteristic. A study conducted in Taiwan investigated HZ in 10,296 elderly people (≥65 yr of age). Data were compared with 39,405 randomly selected individuals aged ≥65 yr without a diagnosis of HZ. The HZ group showed a hazard rate of 1.17 for the development of Parkinson’s disease. This is important to recognize early symptoms of Parkinson’s disease among elderly people affected by HZ.

**Wolf’s isotopic response**

Even after clinical remission, former HZ lesions represent a *locus minoris resistentiae*, on which other disorders may develop. The phenomenon has been called Wolf’s isotopic response. The phenotypical variety is extraordinarily large. Such postherpetic disorders with Wolf’s response include granuloma annulare, lupus erythematosus, morphoea, lichen planus, molluscum contagiosum or B-cell chronic lymphocytic leukaemia. In such cases, histologic investigations are indispensable.

**Pathergic phenomenon**

Pathergy describes a skin condition, in which a minor trauma leads to the development of ulcerations or other skin lesions that may be resistant to healing. Pathergy can also lead to ulcerations at the site of surgical incisions. Pyoderma gangrenosum of the scalp has been observed as a pathergic response to HZ.

**Herpes zoster as a marker for occult cancer**

In a systematic review and meta-analysis of 46 eligible studies, the pooled relative risk for any cancer was 1.42 and 1.83 at one year after zoster. The highest estimates were noted for haematological malignancies (Fig. 6). A study from Taiwan investigated the hazard rates for cancer after HZ infection in elderly people. Within the first two years after HZ, the risk of subsequent cancer was significantly increased, particularly lung cancer. On the other hand, metastases may resemble HZ. This has been reported for metastatic melanoma, lung cancer, rectal adenocarcinoma, breast cancer and nasopharyngeal cancer among others.

**Erythema multiforme (EM) after herpes zoster (HZ)**

EM is commonly associated with herpes simplex virus infections. It is considered as a hypersensitivity reaction with polymorphous eruptions of macules, papules and targetoid lesions symmetrically distributed.

**Table. Subtypes of herpes zoster associated with specific neurological consequences**

| Subtype                  | Affected nerve                      | Findings                                         | Complications                                      |
|--------------------------|-------------------------------------|--------------------------------------------------|---------------------------------------------------|
| Zoster ophthalmicus      | First trigeminal nerve branch       | Keratitis, blepharitis, keratoconjunctivitis      | Uveitis anterior, orbital phlegmon, retinal necrosis, superior orbital fissure syndrome, blindness |
| Zoster oticus            | Vestibulocochlear and facial nerve  | Pain localized to the ear may also be affected    | Bell’s palsy                                      |
| Ramsay-hunt syndrome     | Vestibulocochlear and facial nerve  | Vesiculation in auditory canal, buccal mucosa, cheeks | Tinnitus, hearing loss, laryngitis, failure of lid closure |

**Fig. 5.** Herpes zoster ophthalmicus with ocular involvement and superimposed bacterial infection.
In contrast, EM has rarely been observed after HZ. Weisman et al\(^{26}\) reported on four patients with HZ with marked increase in VZV antibodies and development of bullous EM about 10-14 days after resolution of HZ. Another patient was reported from Kyoto, Japan, who developed EM after HZ treated successfully with aciclovir\(^{27}\).

**Conclusions**

HZ is a common disease caused by VZV. Although easily recognized by clinical features in the majority of cases, the clinical presentation is variable. The suspicion of HZ in such cases is of particular importance since early treatment is warranted *i.e.* within 72 h after onset of vesicular eruption\(^{28}\).

**Conflicts of Interest:** None.

**References**

1. Wollina U, Machetanz J. Herpes zoster and postherpetic neuralgia. *Hautarzt* 2016; 67: 653-65.
2. Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. *BMC Infect Dis* 2015; 15: 502.
3. Pinchinat S, Cebrían-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: Results from a systematic literature review. *BMC Infect Dis* 2013; 13: 170.
4. Ullsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: Quantifying the burden of disease. *BMC Infect Dis* 2011; 11: 173.
5. Patel LM, Lambert PJ, Gagna CE, Maghari A, Lambert WC. Cutaneous signs of systemic disease. *Clin Dermatol* 2011; 29: 511-22.
6. Zernagt WW, Pauuw DS, O’Connor KM. Varicella zoster with extended prodrome: A case series. *Am J Med* 2013; 126: 359-61.
7. Son JH, Chung BY, Kim HO, Cho HJ, Park CW. Herpes zoster duplex unilateralis: Two cases and brief literature review. *Ann Dermatol* 2016; 28: 757-61.
8. Verma SB, Wollina U. Herpes zoster in pregnancy leading to keloids and post herpetic neuralgia: A double whammy? *Indian Dermatol Online J* 2013; 4: 158-9.
9. Nagel MA, Gilden D. Developments in varicella zoster virus vasculopathy. *Curr Neurol Neurosci Rep* 2016; 16: 12.
10. Minassian C, Thomas SL, SMEETH L, Douglas I, Brauer R, Langan SM. Acute cardiovascular events after herpes zoster: A self-controlled case series analysis in vaccinated and unvaccinated older residents of the United States. *PLoS Med* 2015; 12: e1001919.
11. Wollina U, Schönlebe J. Segmental leukocytoclastic vasculitis in herpes zoster. *Int J Dermatol* 2012; 51: 1351-2.
12. Gilden D, Nagel MA. Varicella zoster virus triggers the immunopathology of giant cell arteritis. *Curr Opin Rheumatol* 2016; 28: 376-82.
13. Wollina U, Gemmeke A. Herpes zoster – associated erythema multiforme. *J Dermatol Case Rep* 2009; 3: 11-3.
14. Lin TY, Yang FC, Lin CL, Kao CH, Lo HY, Yang TY. Herpes zoster infection increases the risk of peripheral arterial disease: A nationwide cohort study. *Medicine (Baltimore)* 2016; 95: e4480.
15. Grahn A, Bergström T, Runesson J, Studahl M. Varicella-zoster virus (VZV) DNA in serum of patients with VZV central nervous system infections. *J Infect* 2016; 73: 254-60.
16. Lai SW, Lin CH, Lin HF, Lin CL, Lin CC, Liao KF. Herpes zoster correlates with increased risk of Parkinson’s disease in older people: A population-based cohort study in Taiwan. *Medicine (Baltimore)* 2017; 96: e6075.
17. Wollina U, Schönlebe J. Disseminated specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia – Wolf’s isotopic response following herpes zoster infection. *J Disch Dermatol Ges* 2016; 14: 179-81.
18. Alani A, Ahmad K. Pyoderma gangrenosum of the scalp: Pathergic response to herpes zoster infection. *Clin Exp Dermatol* 2017; 42: 218-9.
19. Schmidt SA, Mor A, Schonheyder HC, Sørensen HT, Dekkers OM, Cronin-Fenton D. Herpes zoster as a marker of occult cancer: A systematic review and meta-analysis. *J Infect* 2017; 74: 215-35.
20. Chiu HF, Chen BK, Yang CY. Herpes zoster and subsequent risk of cancer: A population-based study. *J Epidemiol* 2013; 23: 205-10.
21. Bergler-Czop B, Brzezinska-Wcislo L, Miziolek B. Metastases of malignant melanoma on the skin of the abdomen and thorax imitating herpes zoster. *Ann Saudi Med* 2017; 37: 84-5.
22. Subramaniam P, Palaniswamy SS, Tewari A. Zosteriform cutaneous metastases from an occult primary malignancy of
lung identified by whole-body FDG PETCT imaging. *Indian J Nucl Med* 2016; 31: 286-8.

23. Reusser NM, Wu W, Mir M. Zosteriform metastasis of rectal adenocarcinoma: A case report. *Dermatol Online J* 2015; 21: pii: 13030/qt0d5455rt.

24. Rao R, Balachandran C, Rao L. Zosteriform cutaneous metastases: A case report and brief review of literature. *Indian J Dermatol Venereol Leprol* 2010; 76: 447.

25. González García A, Fernández EG, Barbolla Díaz I, Ballester A, Pian H, Fraile G. A rare case of zosteriform cutaneous metastases from a nasopharyngeal carcinoma. *Case Rep Dermatol Med* 2015; 2015: 415393.

26. Weisman K, Petersen CS, Blichmann CW, Nielsen NH, Hultberg BM. Bullous erythema multiforme following herpes zoster and varicella-zoster virus infection. *J Eur Acad Dermatol Venereol* 1998; 11: 147-50.

27. Onishi I, Kishimoto S. Erythema multiforme after resolution of herpes zoster by acyclovir. *Eur J Dermatol* 2002; 12: 370-2.

28. Wollina U. Herpes zoster. In: Katsambas A, Lotti T, Dessinioti C, D’Erme AM, editors. *European handbook of dermatological treatments*, 3rd ed. Berlin Heidelberg: Springer; 2015. p. 379-84.

*Reprint requests*: Dr U. Wollina, Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Friedrichstrasse 41, 01067 Dresden, Germany
e-mail: wollina-uw@khdf.de